BIBLIOGRAPHIC RECORD

Centanafadine (Simtriyo®): a first-in-class triple reuptake inhibitor approved for attention-deficit/hyperactivity disorder (ADHD).

This record contains bibliographic metadata. Open the linked source to check the work; the record does not include its full text.

Recorded authors
Hu L
Source of metadata
PubMed
Year recorded
2026

Public identifiers and source

Open the source record

Reference

Hu L. (2026). Centanafadine (Simtriyo®): a first-in-class triple reuptake inhibitor approved for attention-deficit/hyperactivity disorder (ADHD). https://pubmed.ncbi.nlm.nih.gov/42640319/

Reference assembled from the available metadata. Check and cite the original publication before reusing a claim.

Permanent record URL: https://brain.psiconautica.org/en/documentos/d-af1767597b2899994b1a9b41bb664790/